Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
25 /100
LOW RISK
Score updated Sep 12, 2026

ZVRA — Zevra Therapeutics, Inc. Dilution Risk Tracker

Track ZVRA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ZVRA — Get alerts when the score changes →

As of September 12, 2026, Zevra Therapeutics, Inc. (ZVRA) has a DilutionWatch DilutionScore of 25/100, rated LOW dilution risk. Zevra Therapeutics, Inc. has a market capitalization of $685.14M, 59.38M shares outstanding, 149 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
0
📊 Float Risk
10
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for ZVRA.
🔔 Track ZVRA — Get forecast alerts →

Market Data

Market Cap$685.14M
Shares Outstanding59.38M
Float54.96M
Cash$151.15M
Debt$1.15M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore25/100DilutionWatch score record
Shares Outstanding59.38MVerified float table or market cache
Public Float54.96MVerified float table or market cache
Market Cap$685.14MMarket data cache
Cash Runway81.4 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 2.

Recent SEC source mix: XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 27.1% shares (2026Q1 vs prior)
149 institutional holders · 54.20M shares
#1 Woodline Partners LP 6.90M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 4.94M shares
#3 BlackRock, Inc. 4.46M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest5.77M
Days to Cover7.5
% of Float10.5%
FINRA data as of Aug 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2021-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

Factual ZVRA Dilution Snapshot

Zevra Therapeutics, Inc. (ZVRA) has a DilutionScore of 25/100, rated Low dilution risk. Score date: September 12, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track ZVRA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ZVRA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,348+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for ZVRA
ZVRA FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.